Eli Lil­ly steers URLi to­ward the FDA af­ter scor­ing pos­i­tive re­sults in a pair of PhI­II di­a­betes tri­als

Eli Lil­ly’s lu­cra­tive di­a­betes fran­chise got a need­ed boost on Tues­day when the com­pa­ny re­port­ed a fol­low-on can­di­date to its block­buster in­sulin prod­uct Hu­ma­log was found to be as ef­fec­tive in con­trol­ling glu­cose lev­els in a pair of late-stage clin­i­cal tri­als.

Lil­ly said that two Phase III stud­ies showed the new prod­uct, Ul­tra Rapid Lispro (URLi), work as well as Hu­ma­log. The com­pa­ny plans to file for reg­u­la­to­ry ap­proval in 2019. Both URLi and Hu­ma­log are rapid-act­ing in­sulins.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.